三种治疗原发性高血压降压药的成本-效果分析  

Cost-effectiveness analysis of three antihypertensive drugs for essential hypertension

作　　者：李竹英 张磊[2] 

机构地区：[1]湖南省郴州市妇幼保健院药剂科,湖南郴州423000 [2]湖南省郴州市第一人民医院,湖南郴州423000

出　　处：《中国医药导报》2012年第28期123-124,129,共3页China Medical Herald

摘　　要：目的对常用的三种抗高血压药厄贝沙坦、依那普利、美托洛尔进行成本-效果分析。方法选择2010年1月～2011年1月郴州市第一人民医院门诊高血压患者180例为研究对象,并随机分为三组,分别服用抗高血压药厄贝沙坦、依那普利、美托洛尔,疗程12周,根据疗效进行成本-效果分析。结果厄贝沙坦、依那普利组疗效优于美托洛尔组(P<0.05);成本-效果分析,费用效果比最优为厄贝沙坦组。结论药物经济学在为高血压患者合理选药、为患者提高依从性和控制达标率、显著改善患者的生存质量、有效降低疾病负担等方面具有重要意义。Objective To conduct cost-effectiveness analysis for three commonly used antihypertensive drugs -Irvesrtan, Enalapril and Metoprolol. Methods 180 patients with primary hypertension in our hospital enrolled from January 2010 and January 2011 were randomly assigned to receive one of the three antihypertensive drugs-Irvesrtan, Enalapril and Metopro- lol for 12 weeks. Then the cost-effectiveness analysis was done according to the treatment efficacy. Results The treatment efficacy of patients in Irbesartan or Enalapril group were superior to those in Metoprolol group （P 〈 0. 05）. In term of cost--effectiveness, Irbesartan was the best one among the three drugs. Conclusion Pharmacoeconomics is of great impor- tance in the rational drug selection, increase of patients＇ compliance and target-meeting rate, remarkable improvement of patients＇ qualify of life, and effective reduce of patients＇ disease burden for hypertensive patients.

关 键 词：原发性高血压 抗高血压药 药物经济学 成本-效果分析 

分 类 号：R544.1[医药卫生—心血管疾病]